$XBI $148.57 (-0.52%) 📉
PIPELINE:
$ARQT (-0.66%) - Arcutis Initiates Pivotal Phase 3 Clinical Trials Evaluating Topical Roflumilast Cream (ARQ-151) as a Potential Treatment for Atopic Dermatitis https://investors.arcutis.com/news-releases/news-release-details/arcutis-initiates-pivotal-phase-3-clinical-trials-evaluating
$CYTK (-2.08%) - Cytokinetics Announces First Patient Dosed in Cohort 2 of Redwood-HCM
$ELOX (-5.84%) - Eloxx Pharmaceuticals Announces Cystic Fibrosis Foundation (CF Foundation) To Provide Increased Funding and Support for ELX-02 Global Phase 2 Clinical Trial Program
$JNCE (+1.81%) - Jounce Therapeutics Announces Initiation of Phase 1 INNATE Study of JTX-8064 (LILRB2/ILT4 Inhibitor) Monotherapy and PD-1 Inhibitor Combination Therapy in Patients with Advanced Solid Tumors
$RMTI (+5.93%) - Rockwell Medical Announces Dosing of First Patient in Pivotal Triferic® Phase 3 Trial by Partner, Wanbang Biopharmaceuticals, in China
$SESN (-7.50%) - Sesen Bio and Qilu Pharmaceutical Announce IND Application for Vicineum™ Accepted for Review by the National Medical Products Administration in China
$URGN (-3.59%) - UroGen Pharma and MD Anderson Announce Strategic Research Collaboration to Advance Investigational Treatment for High-Grade Bladder Cancer
FINANCIAL:
$ADMS (-2.19%) - Adamas Provides Preliminary Fourth Quarter and Full Year 2020 Total Revenues and Key Business Drivers for 2021
$ESPR (-11.13%) - ESPERION Reports Preliminary Fourth Quarter 2020 Financial Results and Further Commits to Unmet Patient Needs with Oral PCSK9 Inhibitor Program
$SIGA (-2.15%) - SIGA Announces Public Health Agency of Canada Contract Award to Purchase Up To Approximately $33 Million of Oral TPOXX®